Fulcrum Therapeutics(US:FULC) Benzinga·2025-10-10 20:30Core Viewpoint - Fulcrum Therapeutics, a clinical-stage biopharmaceutical company, has granted stock options to new employees as part of its 2022 Inducement Stock Incentive Plan to attract talent in the field of genetically defined rare diseases [1][2]. Group 1: Stock Options Grant - Fulcrum granted a total of 47,450 stock options to new employees at an exercise price of $9.50 per share, which is the closing price on the grant effective date of October 6, 2025 [2]. - Each stock option has a ten-year term and vests over four years, with 25% vesting on the first anniversary of the employee's start date and an additional 6.25% vesting quarterly over the following twelve quarters [2]. Group 2: Company Overview - Fulcrum Therapeutics focuses on developing small molecules aimed at improving the lives of patients with genetically defined rare diseases, particularly in areas with high unmet medical needs [3]. - The company's lead clinical program is pociredir, designed to increase fetal hemoglobin expression for treating sickle cell disease, utilizing proprietary technology to target gene expression [3].